US hospital offers vascular-targeted photodynamic therapy for localised PCa
Thursday, 29 July 2010- The NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localised prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibres in...
Edited by: JV
Dense bones linked to higher prostate cancer risk
Thursday, 29 July 2010- Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, according to new research from Johns Hopkins and the National Institute on...
Most low-risk PCa patients receive aggressive treatment
Wednesday, 28 July 2010- Most men who are diagnosed with prostate cancer appear to under undergo aggressive therapy, even if they have a low prostate-specific antigen (PSA) level and low-risk disease, according to a report in the July 26 issue of Archives of Internal Medicine, one of the...
Edited by: JV
Stone size is the only predictor of ESWL success in children
Wednesday, 28 July 2010- S. McAdams and colleagues conducted a study to determine whether age, gender, body mass index, number of stones, stone location or total stone diameter could independently predict stone-free rates after extracorporeal shock wave lithotripsy in children.
They published...
Edited by: JV
African Americans face higher risk of kidney failure caused by hypertension
Tuesday, 27 July 2010- Regardless of demographics, African American patients with hypertensive nephrosclerosis have a higher rate of developing end stage renal disease (ESRD) than dying prematurely, according to a study appearing in an upcoming issue of the Journal of the American Society of...
Edited by: JV
Gamma-tocotrienol kills prostate cancer stem cells in mice study
Tuesday, 27 July 2010- Scientists from Singapore, Australia and Hong Kong have found that gamma-tocotrienol is potent in killing prostate cancer stem cells. This small group of cells is responsible for the initiation of prostate cancer and is resistant to conventional chemotherapy drugs. It causes...
Edited by: JV
Performance of PCA3 Gene and PSA in pre-screened men
Monday, 26 July 2010- The performance characteristics of serum prostate-specific antigen (PSA) as a diagnostic test for prostate cancer (PCa) are poor. The performance of the PCa antigen 3 (PCA3) gene as a primary diagnostic is unknown.
M. Roobol and colleagues conducted a study to assess the...
Edited by: JV
Higher bone and fracture risks for postmenopausal women with kidney disease
Monday, 26 July 2010- The effect of mild renal dysfunction on bone mineral density and fracture risk is uncertain.
H. Kaji and colleagues evaluated whether mild renal dysfunction would affect bone mineral density (BMD) and the risk of vertebral fractures (VFs) in 659 postmenopausal women. They...
Edited by: JV
HPV vaccine gives protection against genital warts and low-grade pre-cancerous growths
Friday, 23 July 2010- Vaccination against certain types of human papillomavirus (HPV) gives strong and sustained protection against genital warts and pre-cancerous growths of the cervix, according to a new study published in an online edition of the British Medical Journal (BMJ).
An international...
Edited by JV
Nine emerging therapies to boost prostate cancer drug market to more than $8.4b
Thursday, 22 July 2010- Decision Resources, one of the world's research and advisory firms for pharmaceutical and healthcare issues, said that the launch and uptake of nine emerging therapies will drive the prostate cancer drug market to more than double from nearly $4 billion in 2009 to $8.4...
Edited by: JV
